Coronavirus Disease Vaccines (COVID-19 Vaccines)

Summary

The sprint to advance a COVID-19 vaccine is hotly contested. More than 100 vaccines are in preclinical testing, according to the publisher, while 23 companies have moved their candidates into clinical trials. Broadly, some eight different vaccine technologies are in clinical trials: mRNA, DNA plasmid, protein subunit, adenovirus-vectored, measles-vectored, vesicular stomatitis virus-vectored, adenovirus associated-vectored and inactivated virus vaccines. Seven companies have planned or ongoing Phase II/III studies: AstraZeneca, Inovio, Moderna, Novavax, Pfizer/BioNtech, Sinopharm and Sinovac

Key Highlights

• Sixteen catalysts highlighted
• Eight vaccine technologies in clinical trials discussed
• Seven companies with planned or ongoing Phase II/III studies plus others in earlier-stage development analyzed
• Five investigative articles on trial design requirements and launch considerations with an early EUA
• Five to 12 experts cited per article

Scope

• Snapshot of upcoming high-impact, catalytic events for COVID-19 vaccines
• Insights investigative journalism related to COVID-19 vaccine development
• Exclusive analysis of various vaccine technologies' prospects
• Considerations for trial protocols and approvals

Reasons to Buy

• Stay ahead of pipeline developments for COVID-19 vaccines
• Obtain a snapshot of future, key clinical trial events
• Access qualitative asset analysis based on talking to 5-12 KOLs about various vaccines in clinical trials
• Leverage investigative journalism content on prospects for vaccine approvals and market uptake